XML 34 R25.htm IDEA: XBRL DOCUMENT
v3.22.1

Revenue (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2022
Revenue from Contract with Customer [Abstract] |
Schedule of Total Revenue by Category and by U.S versus Rest of World | The following table presents detail regarding the composition of the Company’s total revenue by type and by U.S. versus rest of world (“RoW”):
| Three months ended March 31,
| 2022 |  |  | 2021
(in millions) | U.S. |  | RoW |  | Total |  |  | U.S. |  | RoW |  | Total
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer | $ | 60.7 |  |  | $ | 10.2 |  |  | $ | 70.9 |  |  |  | $ | 65.1 |  |  | $ | 11.0 |  |  | $ | 76.1 |
Tumor Profiling | 19.7 |  |  | 12.8 |  |  | 32.5 |  |  |  | 24.2 |  |  | 6.8 |  |  | 31.0 |
Prenatal | 31.7 |  |  | 0.2 |  |  | 31.9 |  |  |  | 23.6 |  |  | 0.1 |  |  | 23.7 |
Pharmacogenomics | 29.3 |  |  | — |  |  | 29.3 |  |  |  | 17.6 |  |  | — |  |  | 17.6 |
Autoimmune | 0.3 |  |  | — |  |  | 0.3 |  |  |  | 10.7 |  |  | — |  |  | 10.7 |
Other | — |  |  | — |  |  | — |  |  |  | — |  |  | 0.5 |  |  | 0.5 |
Total molecular diagnostic revenue | 141.7 |  |  | 23.2 |  |  | 164.9 |  |  |  | 141.2 |  |  | 18.4 |  |  | 159.6 |
Pharmaceutical and clinical services revenue | — |  |  | — |  |  | — |  |  |  | 13.5 |  |  | — |  |  | 13.5 |
Total revenue | $ | 141.7 |  |  | $ | 23.2 |  |  | $ | 164.9 |  |  |  | $ | 154.7 |  |  | $ | 18.4 |  |  | $ | 173.1 |
Reconciliation of Deferred Revenue Balances | A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
| Three months ended March 31,
(in millions) | 2022 |  |  | 2021
Deferred revenue - beginning balance | $ | 5.2 |  |  |  | $ | 32.7 |
Revenue recognized | (4.8) |  |  |  | (6.7) |
Prepayments | 0.3 |  |  |  | 5.1 |
Deferred revenue - ending balance | $ | 0.7 |  |  |  | $ | 31.1 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration